Phase 3 Trial of Nemolizumab in Prurigo Nodularis 🧬

Created using ChatSlide

This presentation offers an in-depth look at the Nemolizumab trial as detailed in the NEJM article, sponsored by Galderma and registered under NCT04501679. It explores the chronic condition of Prurigo Nodularis and Nemolizumab's role as an IL-31 receptor antagonist targeting itch and inflammation. The study, a Phase 3 multicenter RCT, involved 274 adults and demonstrated significant efficacy in itch reduction and improved patient quality of life. While results prove promising, attention is...